0001745285-19-000009.txt : 20190725 0001745285-19-000009.hdr.sgml : 20190725 20190725191211 ACCESSION NUMBER: 0001745285-19-000009 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190723 FILED AS OF DATE: 20190725 DATE AS OF CHANGE: 20190725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Alex CENTRAL INDEX KEY: 0001711183 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-29089 FILM NUMBER: 19975636 BUSINESS ADDRESS: BUSINESS PHONE: 781-674-4400 MAIL ADDRESS: STREET 1: 3 FORBES ROAC CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGENUS INC CENTRAL INDEX KEY: 0001098972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061562417 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-674-4410 MAIL ADDRESS: STREET 1: 3 FORBES ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ANTIGENICS INC /DE/ DATE OF NAME CHANGE: 19991115 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2019-07-23 0 0001098972 AGENUS INC AGEN 0001711183 Duncan Alex C/O AGENUS INC. 3 FORBES ROAD LEXINGTON MA 02421 0 1 0 0 Chief Technology Officer Stock Option (Right to buy) 2.39 2019-07-23 4 A 0 30000 0 A 2029-07-23 Common Stock 30000 30000 D Stock option awarded in accordance with Agenus Inc. 2019 Equity Incentive Plan and is eligible to vest, if at all, in a single installment on June 30, 2022 based upon the Company stock price performance. Amount shown reflects the target award. The ultimate award size can range between 0% and 150% of target based on the actual average stock price achieved at the end of the performance period. /s/Evan D. Kearns, as Attorney-in-Fact for Alex Duncan 2019-07-25